Beam Therapeutics Inc. BEAM
Set alert
26.84 USD +0.96 +3.73%
As of Nov 3, 1:23 PM ET
25.99 Day range 27.20
20.23 52-week range 38.26
- YTD
- -3.19%
- 1 year
- +10.66%
- Open
- 26.26
- Prev close
- 25.87
- Mkt cap
- 2.77B
- Vol
- 424.85K
- Avg vol
- 1.84M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.99
- High
- 27.20
- Forward P/E
- -5.45
- Beta
- 2.22
- Short ratio
- 13.87
- Inst. own
- 107.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 25.93
- 200-d avg
- 28.14
- 1y target
- 49.38
3M chart
Events in this range
- Aug 4, 2026Earnings: -1.18; estimate -1.11; surprise -6.31%
- Aug 25, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Wedbush · Outperform → Outperform
- Oct 14, 2026Rating: Wedbush · Outperform → Outperform
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 28, 2026Rating: Wedbush · Outperform → Outperform
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Nov 3, 2026Earnings: —; estimate -1.15; surprise —%
Signals (15)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Financial health
Altman Z-Score
3.62 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -34.2×
FY 2017 5y median -13.8× FY 2025
P/S 19.6×
FY 2017 5y median 32.1× FY 2025
P/B 2.2×
FY 2017 5y median 2.8× FY 2025
P/FCF -7.6×
FY 2017 5y median -11.5× FY 2025
EV/EBITDA -196×
FY 2017 5y median -16.5× FY 2025
EV/Sales 19.6×
FY 2017 5y median 30.2× FY 2025
FCF Yield -13.1%
FY 2017 5y median -8.7% FY 2025
Profitability
Gross Margin 84.0%
FY 2017 5y median -347.8% FY 2025
Operating Margin -274.6%
FY 2017 5y median -555.6% FY 2025
Net Margin -57.2%
FY 2017 5y median -474.5% FY 2025
ROE -6.5%
FY 2017 5y median -39.4% FY 2025
ROIC -27.4%
FY 2017 5y median -30.0% FY 2025
ROA -5.4%
FY 2017 5y median -21.5% FY 2025
Growth (YoY)
Revenue 120.0%
FY 2017 FY 2025
Operating Income 7.7%
FY 2017 FY 2025
EPS (diluted) 82.3%
FY 2017 FY 2025
Free Cash Flow -1.1%
FY 2017 FY 2025
Financial Health
Current Ratio 13.1×
FY 2017 5y median 5.9× FY 2025
Quick Ratio 13.1×
FY 2017 5y median 5.9× FY 2025
Debt / Equity 0.2×
FY 2017 5y median 0.2× FY 2025
Net Debt / EBITDA 0.1×
FY 2017 5y median 0.3× FY 2025
Interest Coverage -8.8×
FY 2017 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
